MedTrace Logo

Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

NCT02958956 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236507

Last updated 2018-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes.

Conditions

  • Diabetes Mellitus, Type 2, Cancer

Interventions

DRUG

Pioglitazone

Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-01-01
Primary Completion
2015-05-29
Completion
2015-05-29

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958956 on ClinicalTrials.gov